Testosterone Therapy Without Hypogonadism Linked to Higher Long-Term Cardiovascular Risk
Men who started testosterone therapy (TT) without evidence of hypogonadism had significantly higher long-term risks of major adverse cardiovascular events (MACE), all-cause mortality, ischaemic stroke, cardiac arrest, and heart failure than men with documented hypogonadism. In this global retrospective real-world study of 358,957 men aged 30–75 years initiating TT, 35.4% […]